Entrada Therapeutics (TRDA) Competitors

$6.83 -0.49 (-6.69%)

Closing price 04:00 PM Eastern

Extended Trading

$6.59 -0.24 (-3.51%)

As of 05:09 PM Eastern

TRDA vs. MLYS, RARE, ZLAB, SRPT, and ADPT

Should you buy Entrada Therapeutics stock or one of its competitors? MarketBeat compares Entrada Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Entrada Therapeutics include Mineralys Therapeutics (MLYS), Ultragenyx Pharmaceutical (RARE), Zai Lab (ZLAB), Sarepta Therapeutics (SRPT), and Adaptive Biotechnologies (ADPT). These companies are all part of the "pharmaceutical products" industry.

How does Entrada Therapeutics compare to Mineralys Therapeutics?

Mineralys Therapeutics (NASDAQ:MLYS) and Entrada Therapeutics (NASDAQ:TRDA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

In the previous week, Mineralys Therapeutics had 4 more articles in the media than Entrada Therapeutics. MarketBeat recorded 23 mentions for Mineralys Therapeutics and 19 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 0.47 beat Mineralys Therapeutics' score of -0.09 indicating that Entrada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mineralys Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Entrada Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Mineralys Therapeutics has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.09, indicating that its share price is 109% less volatile than the broader market.

Mineralys Therapeutics presently has a consensus target price of $49.33, indicating a potential upside of 80.91%. Entrada Therapeutics has a consensus target price of $18.25, indicating a potential upside of 167.20%. Given Entrada Therapeutics' higher possible upside, analysts plainly believe Entrada Therapeutics is more favorable than Mineralys Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

Mineralys Therapeutics has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -2,895.05%. Mineralys Therapeutics' return on equity of -27.92% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-27.92%	-26.98%
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%

84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are held by institutional investors. 18.9% of Mineralys Therapeutics shares are held by insiders. Comparatively, 9.5% of Entrada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Entrada Therapeutics has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A
Entrada Therapeutics	$25.42M	10.43	-$143.75M	-$3.99	N/A

Summary

Mineralys Therapeutics beats Entrada Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Entrada Therapeutics compare to Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Entrada Therapeutics (NASDAQ:TRDA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

In the previous week, Ultragenyx Pharmaceutical had 3 more articles in the media than Entrada Therapeutics. MarketBeat recorded 22 mentions for Ultragenyx Pharmaceutical and 19 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 0.47 beat Ultragenyx Pharmaceutical's score of 0.09 indicating that Entrada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Entrada Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Ultragenyx Pharmaceutical has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.09, indicating that its stock price is 109% less volatile than the broader market.

Ultragenyx Pharmaceutical presently has a consensus target price of $60.41, indicating a potential upside of 134.15%. Entrada Therapeutics has a consensus target price of $18.25, indicating a potential upside of 167.20%. Given Entrada Therapeutics' higher possible upside, analysts clearly believe Entrada Therapeutics is more favorable than Ultragenyx Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

Ultragenyx Pharmaceutical has a net margin of -91.03% compared to Entrada Therapeutics' net margin of -2,895.05%. Entrada Therapeutics' return on equity of -51.22% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%

97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are held by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are held by insiders. Comparatively, 9.5% of Entrada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Entrada Therapeutics has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$670M	3.79	-$575M	-$6.11	N/A
Entrada Therapeutics	$25.42M	10.43	-$143.75M	-$3.99	N/A

Summary

Entrada Therapeutics beats Ultragenyx Pharmaceutical on 9 of the 16 factors compared between the two stocks.

How does Entrada Therapeutics compare to Zai Lab?

Zai Lab (NASDAQ:ZLAB) and Entrada Therapeutics (NASDAQ:TRDA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

In the previous week, Entrada Therapeutics had 8 more articles in the media than Zai Lab. MarketBeat recorded 19 mentions for Entrada Therapeutics and 11 mentions for Zai Lab. Entrada Therapeutics' average media sentiment score of 0.47 beat Zai Lab's score of 0.13 indicating that Entrada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral
Entrada Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Zai Lab has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.09, indicating that its stock price is 109% less volatile than the broader market.

Zai Lab presently has a consensus target price of $45.83, indicating a potential upside of 125.45%. Entrada Therapeutics has a consensus target price of $18.25, indicating a potential upside of 167.20%. Given Entrada Therapeutics' higher possible upside, analysts clearly believe Entrada Therapeutics is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.63
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

Zai Lab has a net margin of -39.29% compared to Entrada Therapeutics' net margin of -2,895.05%. Zai Lab's return on equity of -24.32% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-39.29%	-24.32%	-15.52%
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%

41.7% of Zai Lab shares are held by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are held by institutional investors. 4.9% of Zai Lab shares are held by insiders. Comparatively, 9.5% of Entrada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Entrada Therapeutics has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$453.28M	5.09	-$175.54M	-$1.62	N/A
Entrada Therapeutics	$25.42M	10.43	-$143.75M	-$3.99	N/A

Summary

Zai Lab and Entrada Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Entrada Therapeutics compare to Sarepta Therapeutics?

Sarepta Therapeutics (NASDAQ:SRPT) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

Sarepta Therapeutics has a net margin of -2.94% compared to Entrada Therapeutics' net margin of -2,895.05%. Sarepta Therapeutics' return on equity of 7.56% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-2.94%	7.56%	2.94%
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%

Entrada Therapeutics has lower revenue, but higher earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	0.90	-$713.41M	-$0.96	N/A
Entrada Therapeutics	$25.42M	10.43	-$143.75M	-$3.99	N/A

86.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are held by institutional investors. 6.9% of Sarepta Therapeutics shares are held by insiders. Comparatively, 9.5% of Entrada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Entrada Therapeutics had 7 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 19 mentions for Entrada Therapeutics and 12 mentions for Sarepta Therapeutics. Entrada Therapeutics' average media sentiment score of 0.47 beat Sarepta Therapeutics' score of 0.29 indicating that Entrada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Entrada Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Sarepta Therapeutics has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.09, suggesting that its share price is 109% less volatile than the broader market.

Sarepta Therapeutics presently has a consensus target price of $27.71, indicating a potential upside of 48.33%. Entrada Therapeutics has a consensus target price of $18.25, indicating a potential upside of 167.20%. Given Entrada Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Entrada Therapeutics is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	6 Sell rating(s)	13 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.11
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Entrada Therapeutics beats Sarepta Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Entrada Therapeutics compare to Adaptive Biotechnologies?

Adaptive Biotechnologies (NASDAQ:ADPT) and Entrada Therapeutics (NASDAQ:TRDA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

In the previous week, Entrada Therapeutics had 11 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 19 mentions for Entrada Therapeutics and 8 mentions for Adaptive Biotechnologies. Entrada Therapeutics' average media sentiment score of 0.47 beat Adaptive Biotechnologies' score of 0.25 indicating that Entrada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Entrada Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by insiders. Comparatively, 9.5% of Entrada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Adaptive Biotechnologies has a net margin of -16.82% compared to Entrada Therapeutics' net margin of -2,895.05%. Adaptive Biotechnologies' return on equity of -40.06% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%

Adaptive Biotechnologies presently has a consensus target price of $19.57, indicating a potential upside of 48.49%. Entrada Therapeutics has a consensus target price of $18.25, indicating a potential upside of 167.20%. Given Entrada Therapeutics' higher probable upside, analysts clearly believe Entrada Therapeutics is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

Adaptive Biotechnologies has higher revenue and earnings than Entrada Therapeutics. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$295.41M	7.14	-$59.50M	-$0.33	N/A
Entrada Therapeutics	$25.42M	10.43	-$143.75M	-$3.99	N/A

Adaptive Biotechnologies has a beta of 2.16, suggesting that its share price is 116% more volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.09, suggesting that its share price is 109% less volatile than the broader market.

Summary

Adaptive Biotechnologies beats Entrada Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Entrada Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRDA vs. The Competition

Export

Metric	Entrada Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$265.14M	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-1.71	18.81	20.87	25.58
Price / Sales	10.43	181.67	521.63	63.56
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	0.98	6.74	9.86	6.70
Net Income	-$143.75M	$24.11M	$3.55B	$333.77M
7 Day Performance	-0.29%	0.07%	-0.32%	0.45%
1 Month Performance	-51.32%	0.84%	1.34%	4.06%
1 Year Performance	-14.30%	78.10%	41.03%	36.21%

Entrada Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRDA Entrada Therapeutics	3.6755 of 5 stars	$6.83 -6.7%	$18.25 +167.2%	-15.9%	$265.14M	$25.42M	N/A	110	Earnings Report Analyst Revision High Trading Volume
MLYS Mineralys Therapeutics	3.6211 of 5 stars	$29.28 -1.2%	$49.14 +67.8%	+76.8%	$2.44B	N/A	N/A	28	Insider Trade Analyst Revision
RARE Ultragenyx Pharmaceutical	3.2571 of 5 stars	$25.01 +0.8%	$60.76 +143.0%	-25.3%	$2.44B	$673M	N/A	1,371	Analyst Downgrade Analyst Revision
ZLAB Zai Lab	3.9375 of 5 stars	$20.98 -1.1%	$50.00 +138.3%	-28.5%	$2.41B	$460.16M	N/A	1,784	Earnings Report Analyst Downgrade
SRPT Sarepta Therapeutics	3.4616 of 5 stars	$21.79 -1.1%	$32.63 +49.7%	-48.0%	$2.33B	$2.20B	N/A	1,372	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRDA) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Entrada Therapeutics (TRDA) Competitors

TRDA vs. MLYS, RARE, ZLAB, SRPT, and ADPT

How does Entrada Therapeutics compare to Mineralys Therapeutics?

Summary

How does Entrada Therapeutics compare to Ultragenyx Pharmaceutical?

Summary

How does Entrada Therapeutics compare to Zai Lab?

Summary

How does Entrada Therapeutics compare to Sarepta Therapeutics?

Summary

How does Entrada Therapeutics compare to Adaptive Biotechnologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA vs. The Competition

Entrada Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Entrada Therapeutics (TRDA) Competitors

TRDA vs. MLYS, RARE, ZLAB, SRPT, and ADPT

How does Entrada Therapeutics compare to Mineralys Therapeutics?

Does the media refer more to MLYS or TRDA?

Which has more risk and volatility, MLYS or TRDA?

Do analysts recommend MLYS or TRDA?

Is MLYS or TRDA more profitable?

Do insiders and institutionals believe in MLYS or TRDA?

Which has stronger valuation & earnings, MLYS or TRDA?

Summary

How does Entrada Therapeutics compare to Ultragenyx Pharmaceutical?

Does the media refer more to RARE or TRDA?

Which has more volatility & risk, RARE or TRDA?

Do analysts prefer RARE or TRDA?

Is RARE or TRDA more profitable?

Do institutionals and insiders believe in RARE or TRDA?

Which has higher earnings & valuation, RARE or TRDA?

Summary

How does Entrada Therapeutics compare to Zai Lab?

Does the media refer more to ZLAB or TRDA?

Which has more volatility & risk, ZLAB or TRDA?

Do analysts prefer ZLAB or TRDA?

Is ZLAB or TRDA more profitable?

Do institutionals and insiders believe in ZLAB or TRDA?

Which has higher earnings & valuation, ZLAB or TRDA?

Summary

How does Entrada Therapeutics compare to Sarepta Therapeutics?

Is SRPT or TRDA more profitable?

Which has better earnings and valuation, SRPT or TRDA?

Do institutionals and insiders believe in SRPT or TRDA?

Does the media prefer SRPT or TRDA?

Which has more risk & volatility, SRPT or TRDA?

Do analysts prefer SRPT or TRDA?

Summary

How does Entrada Therapeutics compare to Adaptive Biotechnologies?

Does the media prefer ADPT or TRDA?

Do institutionals and insiders believe in ADPT or TRDA?

Is ADPT or TRDA more profitable?

Do analysts prefer ADPT or TRDA?

Which has better earnings and valuation, ADPT or TRDA?

Which has more risk & volatility, ADPT or TRDA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA vs. The Competition

Entrada Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools